著者
Yousuke FURUTA Takashi KOMENO Takaaki NAKAMURA
出版者
The Japan Academy
雑誌
Proceedings of the Japan Academy, Series B (ISSN:03862208)
巻号頁・発行日
vol.93, no.7, pp.449-463, 2017-08-02 (Released:2017-08-02)
参考文献数
61
被引用文献数
1 61

Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti-viral activity against the influenza virus by Toyama Chemical Co., Ltd. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.

言及状況

外部データベース (DOI)

Twitter (7 users, 7 posts, 13 favorites)

@hajiro826 @TaeSapunapi 仰るとおりです 実際そのため制限されてきたわけですからね https://t.co/6VoOYafMrb ”ファビピラビルは催奇形性および胚毒性のリスクがあります。そのため、厚… https://t.co/o68nKdU0bE
こっちのほうがまだ分かりやすい。ファビピラビルRTPってのがインフルに限らずRNAウイルス全般に有効ってことらしいが、さっぱりわからん。 https://t.co/VJxDxjLWsu
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. https://t.co/Fkr8F7e8ni #COVID19 #CoronavirusPandemic
@fiendOfriend @FeiZV สามารถมาคุยเพิ่มเติมได้ค่ะถ้าคิดว่าเราหลงประเด็น และเราพูดอะไรผิดพร้อมรับฟังค่ะ อันนี้คือหลักฐ… https://t.co/WuHIeEGpUP

収集済み URL リスト